Company: DMAC
Filing Date: 2025-08-06
Form Type: 8-K
Source: 0001437749-25-024956
Chunk: 0

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-08-06
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective August 4, 2025, Lorianne Masuoka, M. D. resigned as Chief Medical Officer of DiaMedica Therapeutics Inc. (the “ Company”), effective as of August 4, 2025, for personal reasons.

In connection with Dr. Masuoka’s departure, the Company and Dr. Masuoka entered into a separation and release agreement (“ Separation Agreement”) effective August 4, 2025, providing for the continuation of health benefits to Dr. Masuoka through October 2026.

The foregoing is a summary description of the terms and conditions of the Separation Agreement and is qualified in its entirety by reference to the Separation Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.

Item 7.01Regulation FD Disclosure.